Abstract | Follicular helper T (T FH ) cells are essential for B-cell maturation and immunoglobulin production after immunization with thymus-dependent antigens. Nevertheless, the development and function of T FH cells have been less clearly defined than classic CD4 + effector T-cell subsets, including T-helper-1 (T H 1), T H 2 and T H 17 cells. As such, our understanding of the genesis of T FH cells in humans and their role in the development of autoimmunity remains incomplete. However, evidence from animal models of systemic lupus erythematosus (SLE) and patients with systemic autoimmune diseases suggests that these cells are necessary for pathogenic autoantibody production, in a manner analogous to their role in promotion of B-cell maturation during normal immune responses. In this Review, I discuss the findings that have increased our knowledge of T FH -cell development and function in normal and aberrant immune responses. Such information might improve our understanding of autoimmune diseases, such as SLE, and highlights the potential of T FH cells as therapeutic targets in these diseases.
Introduction

CD4
+ T cells have a crucial role in helping B cells pro duce antibodies in response to challenge with foreign antigens. The interaction between these cell types typi cally occurs in germinal centres (GCs) located within the Bcell follicles of secondary lymphoid organs-sites of immunoglobulin affinity maturation and iso type switch ing. GCs are formed during Tcelldependent (thymus dependent) immune responses, which involve a specialized CD4 + Tcell subset, follicular helper T (T FH ) cells. The T FH cells localize to Bcell fol licles and provide B cells with important survival and dif ferentiation signals, via proteins including CD40 ligand (CD40L, also known as CD154), programmed death1 (PD1), and IL21. T FH cells also produce fac tors essential for Bcell selection and maturation into memory B cells or longlived antibody secreting plasma cells. During Tcelldependent immune responses, extrafollicular foci of plasmablasts form in the red pulp of the spleen and the medullary cords in lymph nodes; this process also requires CD4 + T cells with features characteristic of T FH cells. Similarly, pathogenic auto antibodies seem to be produced via both GC and extrafollicular pathways in systemic autoimmune diseases. These activities of T FH cells-and cells with similar properties that promote extrafollicular responses-differ from those of conven tional CD4 + effector T cells. When aberrantly regulated, cells of the 'classical' effector Thelper1 (T H 1), T H 2 and T H 17 subsets can migrate to the periphery, where they augment inflammation, as occurs in the kidney in systemic lupus erythematosus (SLE) or in the brain in multiple sclerosis, or in allergic responses-in the asthmatic lung, for example. The influence of T FH cells on Bcell responses plays an equally important part in the development and perpetuation of systemic auto immunity. In this Review, I describe the development and charac teristics of T FH cells, and discuss the functions of these cells during normal immune responses and in autoimmune disease in mice and humans.
Effector CD4 + T helper cells
T helper cells are central to the regulation of immune responses. In primary immune responses, CD4 + T cells promote immunoglobulin affinity maturation and class switching in B cells, and inflammatory and allergic events in parenchymal tissues. CD4 + Tcell subsets that possess either B helper or inflammatory (or allergic) activity differen tiate from a common naive CD4 + Tcell pre cursor after antigen stimulation in secondary lymphoid tissues. 1 In order to provide Bcell help, T cells must migrate to Bcell follicles and ultimately GCs (or extra follicular foci) in secondary lymphoid organs, whereas inflammatory Tcell subsets localize to peripheral tissues in response to inflammation or to allergic stimuli. Development of the specialized functions of each of the CD4 + Tcell subsets is determined by specific cell-cell interactions and cytokines, which regulate differentiation by driving expression of particular transcription factors. The transcription factor produced subsequently controls expression of the repertoire of surfacebound and soluble factors that dictate cell function, as well as chemokine receptors and adhesion molecules that regulate locali zation to specific tissues. Thus, separable effector Tcell subsets can be defined by lineagespecific transcription drives production of the cytokines IL4, IL5, and IL13 ( Figure 1 ). 4 These cytokines are essential for clearance of helminths (worms) and other extracellular pathogens and, in particular genetic and environmental contexts, are drivers of pathological allergic responses.
T H 17 cells
T H 17 cell differentiation occurs in response to IL6 and transforming growth factorβ. The T H 17 cell phenotype is dictated by retinoidrelated orphan receptor (ROR)γt (RORγt)-induced by hypoxiainducible factor 5 -and RORα, which control transcription of IL17 (Figure 1 ). 6, 7 IL17 promotes neutrophil recruitment and activation, and is key to the elimination of extracellular bacteria, such as streptococci, and fungi. T H 17 cells can also produce IL22, 8 a cytokine also secreted by other CD4 + Tcell subsets, which is required for regulation of host defences by cell populations at epithelial barriers. 9 Like their T H 1 and T H 2 cell counterparts, T H 17 cells promote autoimmunity when abnormally activated, contribut ing to tissue inflammation in classical Tcellmediated diseases such as multiple sclerosis, 10 inflammatory arthritis, 11 and, as more recently demonstrated, in end organ damage in SLE. 12 Furthermore, IL22producing T H 17 cells have a causal role in the development of pathogenic skin lesions in inflammatory skin disorders. 9 Together with cytotoxic CD8 + T cells that are neces sary for viral immunity, the classical CD4 + effector Tcell sub sets coordinate responses to the range of pathogens -viruses, worms, fungi and intracellular and extra cellular bacteria-encountered by mammals. When aber rantly regulated, these cells promote tissue injury in a variety of autoimmune, inflammatory or allergic diseases.
CD4 + T FH cells
Antibody production is crucial for pathogen clearance and prevention of reinfection, with Bcell responses to most protein antigens strictly Tcelldependent; there fore, CD4 + Thelpercelldependent Bcell help is essen tial. 13 Collaboration between T cells and B cells during a Tcelldependent immune response results in the forma tion of extrafollicular foci of antibody secreting cells 14, 15 and GCs within Bcell follicles. 14, 16, 17 After T cells and B cells have been primed by antigen encounter, interactions that initiate development of extrafollicular foci or GCs occur at the border of the Tcell zone and Bcell follicle (the Tcell-Bcell border) in the spleen, 14, 16, 18 or in the interfollicular region of lymph nodes. 19 In order to appreciate how T FH cells are identified, one must first understand the migration of activated T cells and B cells to these sites of interaction: patterns of expression of receptors that enable such movement, as well as the expression of other surface proteins associated with migratory processes, are used to characterize T FH cells in healthy individuals and patients with disease using flow cytometry. In addition, analysis of transcriptional regulation and protein expression is important to understand T FH cell function. In the fol lowing sections, I will elaborate these concepts in more detail, mainly on the basis of data obtained in mice. T cells into different T-helper-cell subsets is dependent on factors present in the local environment, most prominently cytokines. The specific stimulatory conditions influence transcription factor expression, which determines the differentiation program that the T cell will follow and thus the cytokines that it will subsequently produce. The pattern of cytokine expression characterizes the individual T-helper-cell subsets and dictates their function in host defenses. Whereas the cytokine signals that promote the development of T H 1, T H 2, T H 17, and T REG cells are well-defined, less is known about those that drive T FH -cell formation, but seem to include IL-6 and IL-21. 76 Abbreviations: BCL6, B-cell lymphoma 6; FOXP3, forkhead box protein 3; GATA3, GATA-binding factor 3; RORα, retinoid-related orphan receptor-α; RORγt, retinoid-related orphan receptor-γt; TBX21, T-box transcription factor TBX21; T FH , follicular helper T; TGF-β, transforming growth factor-β; T H 1, T-helper-1; T H 2, T-helper-2; T H 17, T-helper-17; T REG , regulatory T.
Migration and identification of T FH cells
Cells destined to develop a T FH cell phenotype undergo antigen priming by dendritic cells (DCs) in Tcell zones of secondary lymph nodes (Figure 2 ). Antigen priming is accompanied by costimulatory signals, such as those propagated through B7 interactions with CD28 and inducible Tcell costimulator (ICOS)-which is upregulated on T cells upon their activation-and its ligand, ICOSL, expressed on DCs. 20 These stimuli lead to changes in expression of chemokine receptors on activated T cells; for example, CCchemokine recep tor 7 (CCR7) is downregulated. Initial entry of naive T cells into secondary lymphoid organs from the circu lation requires engagement of CCR7 by its chemokine ligands CCchemokine ligand (CCL) 19 and CCL21 expressed on high endothelial venules (in lymph nodes) and on Tcell zone reticular cells (in the spleen and lymph nodes). [21] [22] [23] [24] Coincident with CCR7 downregula tion, expression of the cell adhesion molecule Pselectin glycoprotein ligand1 (PSGL1) is reduced. 25 PSGL1 is also expressed on naive T cells and engages CCL19 and CCL21 to facilitate Tcell zone entry. 26 These changes in chemokine receptor, and presumably in PSGL1 expres sion, release activated T cells from the chemotactic influence of CCL19 and CCL21, [21] [22] [23] [24] enabling Tcell zone egress.
In addition to downregulation of CCR7 and PSGL1, concomitant and sustained CXCchemokine recep tor 5 (CXCR5) upregulation 27, 28 enables newly activated T cells to enter the Bcell follicle, by following a gradi ent of its ligand CXCchemokine ligand (CXCL) 13 (also known as Blymphocyte chemoattractant; BLC) expressed therein ( Figure 2) . 29, 30 Thus, T FH cells have a characteristic surface phenotype, characterized by low CCR7 and PSGL1, and high CXCR5 expression, which is dictated by their need to emigrate from their initial site of development in the Tcell zone to their site of function in the Bcell follicle.
T FH cells continue to express ICOS after activation by DCs to enable subsequent Bcell driven maintenance and expansion. 20, 24, [31] [32] [33] [34] Indeed, ICOS is necessary for both the GC 35 and extrafollicular responses; 36 in the absence of ICOS signalling, T FH cell development is markedly impaired. 31, 32, 37, 38 T FH cells also upregulate PD1 as they develop in the Tcell zone, a molecule essential for their eventual function in GCs. 39 Collectively, these cell surface markers enable T FH cells to be identified as a CCR7 lo PSGL1 lo CXCR5 hi ICOS hi PD1 hi cell popula tion. This characteristic phenotype-in addition to pro viding a migratory history within secondary lymphoid organs and helping to determine function-is important for flow cytometric and microscopic identification of T FH cells in studies of immunity and autoimmunity.
In an analogous manner to T FH cells, antigen activa tion of B cells causes them to upregulate CCR7 and sub sequently migrate toward the Tcell zone, 40 where they can interact with T cells. The Epstein-Barr virusinduced Gproteincoupled receptor 2 (EBI2) also has an impor tant role in the proper positioning of B cells within the follicle, enabling migration of recently activated B cells to the outer follicular regions and Tcell-Bcell border via an oxysterol gradient. 41, 42 After interacting with T cells in the Tcell-Bcell border or interfollicular regions, a ntigenprimed B cells downregulate EBI2 43, 44 and main tain expression of CXCR5. Thus, by following a CXCL13 gradient, B cells traffic back to the Bcell follicle and even tually to GCs, where they meet their CXCR5expressing T FH cell counterparts (Figure 2 ).
At the sites of initial Tcell-Bcell contact in the inter follicular region of lymph nodes or along the Tcell zone/Bcell follicle border in the spleen, SAP (SLAM associated protein)-an adaptor molecule for the sig nalling of SLAM (signalling lymphocytic activation molecule) family receptors-expressed by T FH cells is required for their stable interaction with primed B cells; lack of SAP results in failed GC formation and impaired humoral immunity. [45] [46] [47] At these initial contact points, T cells also provide their cognate B cells with CD40L and cytokine signals, such as those induced by IL4 ( Figure 3 ), 48 promoting a maturation process-i ncluding initiation of class switch recombination-that is com pleted after they localize to GCs. In return, B cells aid T FH cell expansion and development via ICOSLinduced and antigeninduced signalling ( Figure 3) ; however, provision of antigen by B cells, in contrast to presenta tion by DCs, does not seem to be a limiting factor for T FH cell maturation. 49 T FH cells remain in secondary lymphoid organs after having been activated in the Tcell zone and migrating to sites of Tcell-Bcell contact. By contrast, effector T helper cells eventually downregulate the expression of CCR7, 50 and acquire the ability to express appropri ate selectin ligands, integrins and chemokine receptors for lymphoid organ exit and trafficking into inflamed tissues; [51] [52] [53] expression of the latter molecules is sufficient to dictate peripheral migration of CCR7 hi effector cells.
54
T FH -cell development and B-cell lymphoma 6 Bcell lymphoma 6 (BCL6) is a highly conserved, zincfinger domaincontaining transcriptional repres sor that was originally identified in GC B cells and is necessary for GC formation. 55, 56 BCL6 is also selectively expressed in T FH cells compared with other CD4 + Tcell subsets. 32, 57 In a manner analogous to the roles of the transcription factors TBX21, GATA3, and RORγt and RORα in the differentiation of T H 1, T H 2, and T H 17 cells, respectively, 2,3-6 Tcellintrinsic activity of BCL6 is required for T FH cell development and Tcell depend ent GC responses ( Figure 1) ; 33, 58, 59 overexpression of this protein is sufficient to dictate the T FH cell pheno type. 33 Under the influence of appropriate cytokine signals, including the diminished negative regulatory effect of IL2induced signal transducer and activator of transcription 5 activity, 60 BCL6 is initially upregulated in CD4 + T cells after antigen and ICOS stimulation by DCs in Tcell zones. 19, 20, 34, 61 In the nascent T FH cells, BCL6 then represses a program of gene expression that enables differentiation of other CD4 + effector Tcell subsets, effectively blocking their development. 33, 58, 59 Concurrently, BCL6 promotes expression of molecules that are required for the T FH cell phenotype, including those necessary for their migration and function such as CXCR5, PD1 and CXCR4, at least to some extent by repressing expression of inhibitory microRNAs (miRNAs). 59 BCL6 also downregulates expression of molecules required for Tcell zone retention, promot ing egress of T FH cells toward the Bcell follicle. 25 The detection of BCL6 expression in T FH cells, and dissection of its function therein, provided evidence that these cells represent a CD4 + Thelpercell subset independent of the T H 1, T H 2 and T H 17 lineages.
T FH -cell function in normal immune responses T FH cells have an essential role in provision of Bcell help during the response to Tcelldependent antigens, which relies on their localization to the Bcell follicle 62 and ulti mately to the GC. [63] [64] [65] The latter is the primary site for Bcell somatic mutation with affinity maturation 17, 66 and
GC B cell
Af nity maturation and immunoglobulin class switching immunoglobulin class switching, 67 and thus subsequent emergence of Bcell memory and longlived plasma cells that produce highaffinity antibodies. Bcell help in the GC is mediated partly by a cytokine produced by T FH cells, IL21, 57 which binds IL21R on GC B cells and cooperates with Bcell receptor and CD40 engage ment to promote Bcell proliferation and maturation ( Figure 3) . [68] [69] [70] [71] [72] [73] IL21 is essential for GC development and maintenance, and subsequent development of antibody forming cells. [74] [75] [76] Furthermore, in conjunction with IL4, IL21 drives immunoglobulin class switching. 77 As the IL4 example indicates, T FH cells also secrete cytokines-in addition to the their canonical cyto kine, IL21-that are associated with T H 1, T H 2 and, under certain circumstances, T H 17 cells. [78] [79] [80] This flexibility -or plasticity-in T FH cell differentiation, presum ably dictated at a transcriptional level, 81 enables the secre tion of cytokines that regulate production of immuno globulin isotypes appropriate for clearance of the invad ing pathogen; for example, IFNγ secretion crucial for Bcell class switching to inflammatory immuno globulin iso types, or IL4dependent IgE synthesis that aids c learance of helminths.
Other molecules produced by T FH cells are also neces sary for their function. The inhibitory receptor PD1 is highly expressed on this Tcell subset, and signalling through its ligands PDL1 (B7H1) and PDL2 (B7DC) on GC B cells ensures the ultimate quality of the T FH cell driven response. 39 PD1, in concert with IL21 and IL4, is required for downstream Bcell function, survival in GCs and, ultimately, robust production of plasma cells. 39 By contrast, abrogation of PD1 signalling, especially early in the GC response, enhanced T FH cell numbers and initial immunoglobulin responses. 82 These find ings demonstrate the complexity of signalling via this pathway, and highlight the need to consider both benefi cial and adverse events that might be associated with potential therapeutics targeting PD1.
As noted above, CD40L expressed on T FH cells also has a role in GC development and function; 35 deletion of the gene encoding this protein-for example in human hyperIgM syndrome 83 or experimentally in mice 84 -results in an absence of GC formation. Similarly to IL4 and ICOS signalling, the function of CD40L in Bcell maturation after immunization with Tcelldependent antigens is first manifest at initial sites of Tcell-Bcell contact, before GC entry of nascent T FH cells and matur ing B cells; 48 therefore, the signals that are typically associated with the mature GC response could initially be important at sites of early Tcell-Bcell collabora tion, with these interactions continuing as GCs develop and mature.
Extrafollicular T helper cells
Extrafollicular foci in secondary lymphoid organs are sites where shortlived plasma cells emerge after immuni zation with Tcelldependent (or with t hymus independent) antigens in conventional immune res ponses. 14, 15 In comparison with our understanding of T FH cells, knowledge of the T helper cells that drive the extra follicular response is relatively limited. Within 2 days after primary immunization, CD4 + T cells pro liferate in the Tcell zone, 85 together with the B cells destined to join the extrafollicular response as plasma blasts. 15 Whereas initial interactions between DCs and T cells required for the extrafollicular response are CD40L-CD40independent, subsequent Bcell prolifera tion and plasmablast formation are dependent on these proteins, 48 and on ICOS.
36,86
The CD4 + T cells that promote the extrafollicular response have been defined in mice; like T FH cells, they upregulate BCL6, are dependent on ICOS for their develop ment and express molecules necessary for Bcell maturation, including PD1, CD40L and IL21 ( Figure 4) . 36, 87 Such cells are found in conjunction with B cells at the Tcell-Bcell border after immunization. 87 
Follicular helper iNKT cells
In addition to development of antibodies targeting pro teins after immunization with thymusdependent anti gens, B cells also produce classswitched anti bodies to lipids, which represent a crucial component of immune responses to pathogens. Lipiddriven Bcell help is pro vided by invariant natural killer T (iNKT) cells, which recognize lipids presented in the context of the non classical antigenpresenting molecule CD1d expressed on B cells (among other cell types). 88, 89 The discovery of GCresident iNKT cells in 2011 has offered further mecha nistic insights into the antilipid response. 90, 91 Similar to classical T FH cells, these follicular helper iNKT cells are dependent on BCL6 and Bcell inter actions for development (Figure 4) . 90 Further more, they provide cognate help for Bcell maturation in extra follicular foci and GCs via IL21, resulting in the production of class switched and affinitymatured antibodies to lipids. 90, 91 Although follicular helper iNKT cells did not promote longlived plasma cells or longterm humoral immunity, in contrast to classical T FH cells, they were needed for rapid extrafollicularfoci dependent and GCdependent immunoglobulin responses to lipid antigens.
90,91
Follicular regulatory T cells
Logically, regulatory pathways need to be engaged to prevent loss of selftolerance in GCs and subsequent autoantibody production, 92 given the rapid emergence of somatically mutating Bcell clones at these site follow ing Tcelldependent antigen immunization. 17, 66 The identi fication of follicular regulatory T (T FR ) cells highlights a novel mechanism that controls the normal GC response and presumably prevents emergence of auto reactive Bcell clones. [93] [94] [95] [96] T FR cells are a thymicallyderived population compris ing some 5-25% of GC T cells in mice and humans. 93, 95 This CD4 + Tcell subset demonstrates features of the natural regulatory T (T REG )cell phenotype, including forkhead box protein 3 expression and immuno sup pressive capacity, while expressing markers of classical T FH cells, including CXCR5 and PD1, [93] [94] [95] but not IL21 (Figure 4) . 93 Similar to T FH cells, T FR cell develop ment also depends on BCL6 expression 93, 95 and Bcell inter actions, partially mediated by SAP. 93 In contrast to the helper capacity of T FH cells, T FR cells necessarily function to limit potentially pathogenic GC responses, including the expansion of nonantigen spe cific and potentially autoreactive B cells, 93 via inhibition of T FH cells and GC Bcell maturation; evidence also sug gests that T FR cells regulate plasma cell development. [94] [95] [96] [97] In addition to expression of molecules associated with T REG cells-such as cytotoxic Tlymphocyteassociated antigen 4 and glucocorticoidinduced TNF receptor related protein-that possibly contribute to their sup pressive capacity, T FR cells also abundantly express IL10, 93, 95 which might be important for the regulatory role of these cells in the GC. 96 
T cells and B-cell help in humans
Phenotype of germinal centre T FH cells Our current understanding of T FH cell biology and func tion, as discussed above, is mainly derived from inves tigations performed in mice; however, data on similar Tcell populations that provide help to B cells in humans do exist. Immunohistochemical studies performed nearly three decades ago identified a population of CD4 + GC T cells that stained for the NK cell marker CD57. [98] [99] [100] 
CD57
hi GC T cells are CXCR5 hi and CCR7 lo (indicating that they have exited the Tcell zone), and efficiently help B cells produce antibodies in vitro. 100 Nonetheless, CD57 lo T cells that contain stores of preformed CD40L are also found in the GC, 101 103 are also exclusively located in GCs and are efficient in helping B cells to produce antibodies in vitro in a CD40L dependent manner. 100 These findings suggest a scenario in which GC T helper cells in humans express CXCR5, PD1, ICOS, CD40L and CXCL13 (Figure 4) , and have low (if any) expression of CCR7 and PSGL1, analogous to mouse T FH cells, with downregulation of IL7Rα.
Circulating T FH cells
Peripheral blood is the most convenient tissue for analyses of control individuals and patients with auto immune diseases; therefore, whether T FH cells reside in the circulation and, if so, how their phenotype reflects what is seen in secondary lymphoid tissues are impor tant considerations. In this regard, studies have focused upon characterization of CD4 + T cells that have the capacity to recirculate to secondary lymphoid organs, where they can interact with B cells. Such recirculat ing central memory cells are defined by cell surface markers, specifically CCR7 and Lselectin-both of which are necessary for reentry into lymph nodes-and CXCR5, indicative of the ability to enter Bcell follicles and provide Bcell help. [63] [64] [65] 104 Although conveying a memory phenotype, the circulating CXCR5 hi cells might be relatively shortlived compared with the CXCR5 lo memory population. 63 Upon exposure to CCL19 and CCL21 in vitro, CXCR5 hi cells downregulate CCR7 -similarly to T FH cells that necessarily need to emigrate to the Bcell follicle from the Tcell zone-suggesting that they have the capacity to become T FH cells after re entry into secondary lymphoid organs. 63 105 suggesting that an altered T FH cell regulation might play a part in the pathogenesis of systemic auto immune dis eases. Interestingly, a CXCR5 hi CD4 + central memory Tcell population has also been identified in mice, and these cells have the capacity to recirculate to lymphoid tissue and promote naive Bcell activation. 106 Although expression of CXCR5 and the resultant capacity to enter Bcell follicles correlates with Bcell helper func tion, one should note that a population of tonsillar CXCR5 lo ICOS lo cells, which reside outside Bcell folli cles, can also provide help to naive and memory B cells through CD40L, IL21 and IL10 secretion in vitro. 104, 107 Similarly, CXCR5 lo cells from the peripheral blood can also provide Bcell help, suggesting that at least the portion of the cells with such helper capacity are derived from a CXCR5 hi cell subset. 65 These findings are intriguing; however, the relation ship between circulating CXCR5 hi memory cells and T FH cells localized to Bcell follicles is not entirely clear. This dilemma stems partly from the natural history of the GC response, and presumably the T FH cell response; as the purpose of GCs is development of persistent memory B cells and longlived plasma cells, these struc tures naturally disappear as these functions are accom plished during the days and weeks following antigen challenge. By contrast, whether T FH cells persist after the GC response remains unknown, although CD4 + T cells are found colocalized with memory B cells in GClike structures in Bcell follicles months after immunization in mice. 108 Although detailed characterization of these persistent GC CD4 + T cells has not been performed, memory T helper cells that promote Bcell responses have been identified in the peripheral blood of humans 105 (albeit relatively shortlived compared with the CXCR5 lo memory pool 63 ) and in secondary lymphoid organs of mice, 106 as noted above. These data suggest that such cells could represent T FH cell precursors that can gain T FH cell functionality after antigen rechallenge, 106, 109 whereas T FH cells per se do not preferentially develop into long lived memory cells. 110 The relationship of such circulat ing CXCR5
hi memory T cells to T FH cells-and thus their potential capacity to generate immunological memory -is highly relevant to the chronicity of human auto immunity, given that such CXCR5 hi cells are expanded in the peripheral blood of patients with systemic auto immune diseases; 105, 111 this topic is discussed in more detail in the following sections.
T FH cells in systemic autoimmunity
T FH cells in mouse models of lupus Mouse models have been instructive in highlighting the role of T FH cells in promotion of systemic autoimmunity. The sanroque mouse exemplifies this paradigm:
112 these animals demonstrate spontaneous GC formation (as is common in mouse models of lupus 113 ) and enhanced T FH cell development in the setting of increased ICOS and IL21 production. Dysregulation of ICOS in this model results from a chemicallyinduced point muta tion in the gene encoding the ubiquitin ligase roquin, a negative regulator of ICOS expression, which sup presses ICOS expression. 112 The sanroque mutation is associated with systemic auto immunity characterized by autoantibody production and immunecomplex mediated glomerulonephritis 112 -features of human SLE. ICOSinduced T FH cell dysfunction and subsequent abnormal Bcell selection in GCs have been shown to be responsible for the SLElike phenotype in sanroque mice. 114 Nevertheless, other work has indicated that the sanroque mutation contributes to auto immunity in an as yet undetermined manner; a deletion in the gene encoding roquin that prevented its expression did not result in the development of autoimmunity, despite evi dence of increased ICOS expression and immune dys regulation in this model. 115 Indeed, while IL21 does not contribute to the lupus phenotype in sanroque mice, 114 other models do support a role for T FH cells and IL21 in disease pathogenesis: for example, the BXSB.Yaa model, in which SLElike autoimmunity is promoted by exces sive signalling induced by selfRNA autoantigens as a result of duplication of the gene encoding TLR7. 116 Like sanroque animals, BXSB.Yaa mice have spon taneous GC formation with marked T FH cell expansion and IL21 production. 71 T FH cells also expand beyond GCs to populate extra follicular sites as BXSB.Yaa animals age. 117 The excessive autoantibody production and immune complex mediated glomerulonephritis that characterize this strain are abrogated with genetic disruption of IL21 signaling, 117 presumably secondary to requirement of this cytokine for Bcell maturation. 74, 75 Although T FH cells undoubtedly contribute to the lupus phenotype in BXSB. Yaa mice, CD4
+ T cells with a T FH celllike phenotype that reside in extrafollicular areas might also promote disease. 117 The role of IL21 in potentiation of SLElike disease is substantiated by the prophylactic effectiveness of blockade of this cytokine in other lupusprone mice with polygenic disease; 118 whether therapeutic blockade after disease onset would be beneficial remains unclear.
Other T FH cell cytokines could be pivotal in develop ment of the lupus phenotype. For example, production of IFNγdependent inflammatory IgG isotypes is the hallmark of lupus in mice; these antibodies deposit in peripheral tissues, including the kidney, and initiate pathways that lead to tissue injury. 119 Similarly, IFNγ dependent responses might be an important factor in the pathogenesis of SLE in humans.
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CD40L signalling, like that of IL21, is necessary for T FH celldependent Bcell maturation in GCs, and blockade of this pathway is therapeutically appealing. Indeed, genetic disruption of CD40L or administration of antiCD40L antibodies is effective in the reduction of lupus in a number of mouse models. [121] [122] [123] More over, antiCD40L therapy has shown promise in a study that enrolled a small number of patients with SLE, with diminished pathogenic autoantibody production and a subsequent reduction in disease activity measures and immune complexmediated glomerulo nephritis being reported after treatment. 124 The therapeutic effects of CD40L blockade in these individuals were presumably secondary to the abrogation of pathogenic T FH cellBcell interactions that occur in SLE, as evidenced by an observed inhibition of GC Bcell maturation. 124 T FH cellindependent effects might contribute to the benefit observed with antiCD40L therapy: activated platelets also upregulate this molecule in SLE, enabling them to interact with CD40 expressed on monocytes, leading to their differentiation in to DCs with the poten tial to activate autoreactive T cells. 125 However, anti CD40L therapy was complicated by the development of thromboembolic disease, apparently triggered by binding of the antibody to platelet Fc receptors together with engagement of the surfaceassociated CD40L and resultant platelet aggregation. 126 Nevertheless, these data suggest that development of different therapeutic approaches to interference with CD40 signalling might be beneficial in SLE.
A role for T FH cell expansion and subsequent aberrant GC responses in SLE is also supported by the results of ICOS blockade. Inhibition of ICOS signal ling, via admini stration of antiICOSL antibodies or genetic ablation of ICOS, interrupts T FH cell development and GC forma tion, reduces autoantibody formation and glomerulo nephritis, and abrogates the disease pheno type in mouse polygenic lupus models. 36, 127 Whether therapeutic block ade of ICOS signalling after disease onset in humans would be beneficial is not clear at present; nonetheless, the therapeutic potential demonstrated in mouse models of lupus 127 has led to initiation of earlystage clinic al trials of antiICOSL agents in patients with SLE.
Extrafollicular T helper cells in mouse lupus
Autoantibody production in lupusprone mouse strains also arises at extrafollicular foci within the spleen and lymph nodes, which represent important sites of Tcell migration and maturation and somatic immunoglobu lin mutation of autoreactive B cells in these animals and other models of inflammatory disease. 36, 117, 128, 129 In lupusprone MRLFas lpr mice, extrafollicular T helper cells express ICOS, CD40L and IL21, drive class switch recombination by upregulating activationinduced cyti dine deaminase in plasmablasts, and promote antibody production by autoreactive B cells (dependant on IL21 and CD40L). 36, 130 These findings are similar to those relating to extrafollicular T helper cells identified in BXSB.Yaa mice. 117 Likewise, (NZB × NZW)F1 animals also spontaneously produce extrafollicular T cells with a helper phenotype. 36 Features of these cells-expression of IL21, CD40L and ICOS, and their requirement for Bcell maturation-are shared with T FH cells; however, unlike T FH cells, extrafollicular CD4 + T cells in MRLFas lpr mice lack expression of CXCR5. 36 In the absence of CXCR5, expression of CXCR4 by these cells presumably enables their movement to the extrafollicular locations that they colonize, via attraction to its ligand CXCL12 (also known as stromalcellderived factor1) expressed in the splenic red pulp and the medullary cords of lymph nodes. 131 Although Bcell maturation and autoantibody produc tion as a result of extrafollicular foci formation is impor tant in mouse models of lupus, 128 the role of this pathway in human SLE remains unknown. Given the contribu tion of the extrafollicular response in promotion of sys temic autoimmunity, consideration of this population of Bcell helpers in the development of new therapeu tic approaches will be important. As the charac teristics of extrafollicular T helper cells overlap with those of T FH cells, therapies that affect the function of the latter will probably disrupt extrafollicular responses as well.
T FH cells in human autoimmunity T FH cells are clearly crucial to the pathogenesis of lupus in mice, whereas knowledge of the involvement of these cells in human SLE remains relatively limited. Their role in promotion of this disease has largely been extrapo lated from the observation that the GC Bcell matura tion pathway is aberrantly regulated, 124, 132 and from analysis of T cells isolated from the blood of patients with SLE (which might be confounded by the incom plete understanding of circulating T FH cells, as discussed above). Abnormal GC reactions in patients with SLE can be detected by analysis of circulating B cells, with a classswitched CD38 hi antibodysecreting population being expanded in patients with active disease. 124 As noted above, intervention with antiCD40L antibodies caused the disappearance of this plasma cell subset and a corresponding decrease in antidoublestranded DNA antibody levels, indicating reliance upon Tcell help for development of these cells. 124 
ICOS
hi cells are found in the blood of patients with SLE; 111, 133 111 The presence of cT FH cells in patients with SLE corre lated with a more severe disease phenotype, although not with disease activity per se. 111 Of interest, cT FH cells phenotypically resembled classical lymphoid T FH cells, but did not express BCL6 and IL21, and their ability to deliver Bcell help was not discussed. 111 However, BCL6 is downregulated in mouse T FH cells as the GC response progresses, 61 but is rapidly reexpressed after Tcell receptor stimulation of circulating CXCR5 hi cells. 104 These findings suggest that cT FH cells could represent bloodborne T FH cell precursors with the potential for rapid CXCR5mediated follicular access and Bcell helper functions. 104, 105 Moreover, the high levels of ICOS and PD1 in cT FH cells indicate that these cells might be targeted by therapies that abrogate Tcell-Bcell collabo ration, as indicated by the effectiveness of blockade of ICOS signalling in mouse models of lupus. 127 Tcell-Bcell aggregates and ectopic GCs have been found in the kidneys of patients with lupus nephritis; 134 Tcellassociated centroblasts-GC B cells-and plasma blasts within these GCs and aggregates, respectively, seemed to be capable of clonal expansion and somatic hypermutation. 134 Ectopic lymphoid structures can also develop in other chronic inflammatory conditions, and have been observed within the synovium in rheumatoid arthritis and spondyloarthritis. 135, 136 Indeed, develop ment of tertiary lymphoid structures containing T cells phenotypically resembling T FH cells is not uncommon in chronic autoimmune and inflammatory diseases, and might be a direct result of the ongoing inflamma tory process underlying these conditions. 136 Presumably, Thelper cells in nonlymphoid tissues can promote Bcell maturation and synthesis of potentially pathogenic autoantibody production, thus potentiating tissue injury, as the lupus nephritis example suggests. However, local antibody production in synovial tissue was not found to be pathogenic in a number of patients with rheumatoid arthritis. 136 Regardless of these data, the responsiveness of T FH cells in tertiary lymphoid organs to therapeutic agents designed to disrupt their more classical roles in GC maturation in the spleen and lymph nodes should be considered. This awareness seems especially impor tant given the role of T FH cells resident within secondary lymphoid organs in systemic auto immunity 112, 114 and inflammatory arthritis. 137 
Conclusions
Experiments from several laboratories indicate that autoreactive T cells are necessary for full penetrance of autoantibody production and disease in SLE and mouse lupus. Nevertheless, the cellular mechanisms that promote autoreactive collaboration between CD4 + T cells and B cells, with resultant effector function, remain incompletely defined. Understanding of the events that initiate or sustain aberrant Tcell-Bcell communica tion and the subsequent pathogenic outcomes of such interaction, including autoantibody production and inflammation, is essential, as interference in these pro cesses is likely to be therapeutically important. Issues of therapeutic toxicity or efficacy could be encountered in the develop ment of agents targeting these pathways; therefore, definition of the mechanistic basis of these collaborative interactions will be crucial. Dissection of the potentially separable roles of effector CD4 + T cells and T FH cells in diseases in which autoantibodies are pathogenic, such as SLE and other systemic autoimmune syndromes, offers a means to better understand disease biology; this knowledge is essential to maintain the pipe line of therapeutic targets, and might ultimately lead to the development of novel treatments.
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